Accordingly, in the present work, we aimed at unraveling the underlying molecular mechanism of action of the nucleolin-mediated intracellular delivery of C6-ceramide to cancer cells and understand the ability of the F3 peptide-targeted DXR/C6-ceramide combination to target ovarian cancer cells, including ovarian CSC. This evidence concerns the gene NUCLEOLIN and ovarian carcinoma.